Johnson & Johnson received European Commission approval for an expanded indication of TECVAYLI® (teclistamab). The approval authorizes its use in combination with daratumumab for adult patients with relapsed or refractory multiple myeloma (RRMM).
This decision introduces a steroid-sparing immunotherapy option for patients as early as the second line of treatment. Eligible patients must have received at least one prior therapy.
Phase 3 clinical data showed statistically significant improvements in progression-free and overall survival compared to standard care. The company anticipates this combination will become a new standard of care for blood cancer patients in Europe.